Novo Nordisk has seen a sharp reset in its share price over the past few years, and that shift is forcing investors to ask whether the current valuation is still supported by its earnings power. With headline-making data for semaglutide across obesity, liver disease and cardiovascular risk, the key issue now is how much of that story is already reflected in what you pay for each krone of profit today. Over the past 3 years the stock price has fallen 58.8%, which puts a lot of weight on the question of how closely the current market value tracks the underlying earnings profile.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.